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Summary Studies using monoclonal antibody MR6, which is thought to bind to the interleukin-4 growth
factor receptor (IL-4R), indicate that IL-4R molecules are upregulated in tumours of epithelial origin and that
radiolabelled MR6 is effective as an in vivo tumour imaging agent. Immunohistochemical analysis of a wide
range of solid tumours using monoclonal antibody MR6 has demonstrated elevated expression of the IL-4R
on a variety of carcinomas. The equivalent normal tissue showed either weak or no expression of this
molecule. No other tumours studied were positive. The molecular weight of the receptor on tumour cells was
indistinguishable from that on normal tissue. These data raise the possibility that the IL-4R is the product of
a novel oncogene such that elevated expression of this growth factor receptor could be involved in the process
of carcinogenesis. Monoclonal antibodies to the IL-4R, such as MR6, may therefore be useful reagents not
only for diagnosis and immunoscintigraphy, but also for in vivo antibody-guided therapy of epithelial cancers.
Monoclonal antibodies to tumour-associated antigens are
becoming increasingly important in clinical oncology. For
tumour imaging, small doses of radiolabelled antibody can
be used in vivo to localise the tumour by gamma-camera
imaging (Mach et al., 1981; Farands et al., 1982; Epenetos et
al., 1985b). For therapy, larger in vivo doses of antibody are
used to target a lethal substance such as a radionuclide or
toxin to the site of the tumour (Larson et al., 1983; Miller et
al., 1983; Epenetos et al., 1984; Spitler et al., 1987).
Although few antigens are truly tumour specific, molecules
such as growth factors have proved to be useful target
antigens on tumour cells (Epenetos et al., 1985a).
Growth factors comprise a family of protein molecules
that regulate cell proliferation and number, with each factor
acting on a different range of cell types. Target specificity
and cell activation are controlled by the specific cell surface
receptors to which these soluble ligands bind. Excessive or
inappropriate expression of the receptor for a growth factor
can contribute to the multistage process of oncogenesis
(Bishop, 1983; Land et al., 1983; Hudziac et al., 1987). Thus,
as in the case of the receptor for epidermal growth factor
(EGF-R), a molecule that is expressed at low levels on
normal cells is present at highly elevated levels on the
equivalent tumour tissue (Ullrich et al., 1984; Merlino et al.,
1984).
Interleukin 4 (IL-4; formerly B cell growth factor, B cell
stimulatory factor-1) is a pleiotropic T-lymphocyte derived
factor that was first identified by its ability to enhance the
proliferation of B lymphocytes that had been stimulated with
anti-IgM antibodies (Howard et al., 1982). More recently it
has also been found to induce T-lymphocyte proliferation
(Lee et al., 1986; Mosmann et al., 1986; Fernandez-Botran et
al., 1986; Hu-Li et al., 1987). Recombinant IL-4 has been
used in cross-linking studies to show that the receptor for
this lymphocyte growth factor/lymphokine has a molecular
weight of approximately 139kD and is present at low levels
on T and B lymphocytes, monocytes, promyelocytes, mast
cells, fibroblasts and some epithelial cell lines (Park et al.,
1987).
We have recently described a monoclonal antibody that
we believe binds to the human IL-4 receptor (Larche et al.,
1988a, b). This antibody, MR6, blocks IL-4 induced T-
lymphocyte proliferation and IL-4 dependent IgE production
by B lymphocytes, and binds to a 145kD protein present at
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low levels on T and B cells, macrophages/dendritic cells, and
some epithelia. In earlier studies we observed strong
expression of MR6 on epithelial tumour cells in thymoma
samples from patients with myasthenia gravis (Willcox et al.,
1987). In this paper we describe the use of monoclonal
antibody MR6 to analyse the expression of the interleukin 4
receptor on a variety of malignant cells and their normal
counterparts, and present preliminary clinical data to suggest
that this antibody may be a useful reagent for in vivo tumour
targeting.
Materials and methods
Tissue samples
The following biopsy and autopsy snap-frozen samples were
analysed: normal tissues (skin, tonsil, jejunum, colon, kidney,
ovary, thyroid, lung, lymph node and spleen); epithelial
tumours of the skin (squamous cell carcinoma, basal cell
carcinoma and Bowen's disease); other epithelial tumours
(carcinoma of the ovary, breast, colon, rectum, bladder and
thyroid, bronchioalveolar adenocarcinoma, small bowel
adenocarcinoma and thyroid adenocarcinoma); non-
epithelial tumours (mesothelioma, phaeochromocytoma, lung
sarcoma, haemangiopericytoma and small intestine
carcinoid).
Antibodies
Primary antibodies MR6 is a mouse IgGI monoclonal anti-
body that was raised in the Department of Immunology,
RPMS (De Maagd et al., 1985). This was used either as a
tissue culture supernatant or as a protein A affinity purified
fraction (10igml-1). LP34 mouse monoclonal anti-human
keratin was from Dakopatts (Copenhagen, Denmark). Ox7
mouse IgGI monoclonal anti-Thy-l.1, which does not bind
to human Thy-1, was used as a negative control (Seralab,
UK).
Secondary antibody for immunofluorescence Mouse mono-
clonal antibodies were followed by fluorescein isothiocyanate
(FITC) conjugated rabbit anti-mouse Ig antibody
(Dakopatts), diluted 1:20 in phosphate buffered saline (PBS)
containing 10% normal human serum to block potential
cross-reactivity with endogenous Ig in the human tissue. No
non-specific binding was observed.
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Immunohistochemical analisis
Frozen sections (5pm) were incubated with primary antibody
for 1 h, washed in PBS, then incubated for 1 h with the
secondary conjugated antibody. After further washing, slides
were mounted in Citiflour AFI aqueous mountant (Citilabs,
London). Details of this method have been published
elsewhere (De Maagd et al., 1985).
Western blotting
Details of this method have been described previously
(Larche et al.. 1988b). Bnrefly. 108 thymocytes or Icm3 of
normal thymus or ovarian carcinoma tissue were lysed in
0.50% NP40 containing pjugml - aprotonin. The solubilised
material was separated by 10% SDS-PAGE followed by
electrophoretic transfer to a mntrocellulose membrane (Bio-
Rad. Watford. UK). Unoccupied charged sites on the
membrane were blocked by overnight incubation at 4-C in
PBS containing 2.5% skimmed milk powder (Marvel,
Cadbury Schweppes Ltd. Birmingham). PBS containing
0.5% skimmed milk powder was used subsequently for all
antibody dilutions and for washing the membranes. Strips of
the membrane were incubated for 2 h with primary antibody
(either MR6 or an isotype-matched negative control),
washed. incubated with peroxidase-conjugated rabbit anti-
mouse Ig antibody (Dakopatts) for 30min and washed
again. The peroxidase reaction was developed using 4-
chloro-l-napthol followed by 3,3-diaminobenzidine.
Tumour imaging with MR6
MR6 was produced as bulk tissue culture supernatant,
purfied by protein A affinity chromatography, tested for
sterilitv and pyrogenicity and coupled to "'In using the
cyclic anhydnrde of Diethylenetniaminepentaacetic acid
(DTPA; Sigma, UK), as previously described (Hnatowich et
al.. 1983). One adult male patient with carcinoma of the lung
was given an intravenous dose of 0.5mg MR6 labelW with
1.2mCi "'In. and a gamma-camera scan performed
immediately and after 24 and 48 h. Anterior, posterior and
whole body scans were taken each time.
Results
Normal tissues
Epithelial cells in tonsil and skin (epidermis) were MR6
negative (Figure la). Weak MR6 staining was seen on
convoluted tubular epithelium in the kidney, basal
epithelium of jejunum and colon (Figure lb), and on
epithelium of ovary, thyroid and some samples of lung.
Scattered MR6 positive macrophage/dendritic cells were seen
in many tissues. In the skin, Langerhans cells were MR6
positive (Figure la). Lymphocytes, although known to be
weakly MR6+ in suspension analysis, did not show
sufficiently strong staining to be visible in tissue sections.
Tumour tissue
All 20 epithelial tumours tested were found to be strongly
MR6 + (Table I, Figure 2a-c). The epithelial nature of these
MR6+ tumour cells was confirmed by immunostaining with
LP34 anti-keratin antibody (Figure 2d and e). Where a
tumour showed MR6 binding, essentially all tumour cells
were MR6 +. All other solid tumours tested were MR6
negative.
Western blotting
Monoclonal antibody MR6 detected a single band with a
molecular weight of approximately 145 kD in extracts of
both ovarian carcinoma tissue (Figure 3) and normal thymus
(Larche et al.. 1988b).
F 1 MR6/IL-4R expression in normal tissues. Indirect
immunofluorescence with monoclonal antibody MR6 shows that
skin epidermal cells are IL-4R negative, although scattered
L ngerhans cells are positive (a): colonic epithelium show-s weak
IL-4R staining (b). Magnification: 1.260 x (a): 1.000 x (b).
Tumour imaging
Immediately after administration of "'1In-labelled mono-
clonal antibody MR6 activity was present throughout the
blood pool (Figure 4a). However, this cleared to reveal
significant uptake of MR6 into the tumour site at 48 h
(Figure 4b).
Disassi
In this paper we show that the antigen detected bv the
monoclonal antibody MR6 (MR6-Ag), which we believe to
be the receptor for interleukin 4, is expressed at abnormally
high levels on tumours of epithelial onrgin. The
corresponding normal epithelia are either MR6 negative or
show only weak expression. These findings together with our
preliminary immunoscintigraphic data indicate that the MR6
antibody may have considerable clinical potential as a
diagnostic and immunotherapeutic agent. Furthermore. since
aberrant or excessive expression of receptors for growth
factors has been implicated in tumorigenesis (UlIrich et al..
1984; Merlino et al., 1984; Berger et al., 1987; Cerny et al..
1986; Harris et al., 1988), our data raise the possibifitx that
for some tumours the receptor for IL-4 is involved in this
process of malignant transformation.
Abnormal expression of these molecules can be due either
to amplification or to structural alteration in the normal
cellular proto-oncogene encoding the receptor protein.
resulting in either an increase in the number of receptor
molecules per cell or in a structural vanrant of the receptor:
alternatively, a related viral oncogene may lead to receptor
expression on an inappropnate cell type (Ullnrch et al.. 1984:912 B. AL JABAARI et al.
Table I
MR6/IL-4R+ twnours MR61IL-4R- twnours
Ovarian carcinomae Mesotheliomab
Carcinoma of breastb Phaeochromocytomab
Carcinoma of colon Lung sarcoma
Carcinoma of rectum Haemangiopericytoma
Carcinoma of thyroid Small intestine carcinoid
Carcinoma of lung
Basal cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma (in situ)
Bowen's disease (cutaneous carcinoma in situ)
Bronchioalveolar adenocarcinoma
Small bowel adenocarcinoma
Thyroid adenocarcinoma
Frozen tissue sections were analysed for binding of monoclonal antibody MR6
(anti-IL-4R) by indirect immunofluorescence. Sections were scored for whether the
tumour cells were MR6+ or MR6-. Where a tumour showed MR6 binding the
majority of ells were found to be MR6+.
"Samples from six different patients were analysed. bSamples from two different
patients were analysed.
Fugwe 2 MR6/IL-4 receptor expression in carcinoma. Indirect immunofluorescence with monoclonal antibody MR6 shows that
essentially all epithelial cells in ovarian (a), breast (b) and cutaneous ((c) Bowen's disease) carcinoma are strongly IL-4R positive.
LP34 anti-keratin staining demonstrates the epithelial nature of the tumour cells in the ovarian (d) and breast carcinoma (e). No
staining of the ovarian carcinoma is seen with the negtive control antibody (f). Magnification: 560 x (e); 900 x (b, d and f);
1.410x (a and c).INTERLEUKIN 4 RECEPTOR EXPRESSION 913
1 2 3
180
116
84
58
48
36
26
Figure 3 Western blot analysis of cell lysates from ovarian
carcinoma using monoclonal antibody MR6. From left to right:
(a) pre-stained molecular weight markers (Sigma, Poole, UK); (b)
MR6 antibody; (c) negative control antibody 0x7.
Merlino et al., 1984). Our Western blotting analysis
demonstrates that the molecular weight of the MR6-Ag/IL-
4R on both normal and malignant tissue is approximately
145kD, indicating that the tumour molecule is not the
product of a truncated gene. This, together with our
observations of low IL-4R expression on some epithelia,
suggests that amplification of the normal cellular proto-
oncogene is the most likely mechanism to be responsible.
However, we cannot exclude the possibility of a minor or
single point mutation encoding a small alteration in the
protein product. The unique molecular weight and normal
tissue distribution of the MR6-Ag/IL-4R suggest that this
molecule is the product of a novel proto-oncogene
(Adamson, 1987).
In our survey of 20 epithelial tumours all were strongly
IL-4R positive. However, to determine whether IL-4R
expression is elevated on all carcinomas will require analysis
of a much larger number of samples; these studies are in
progress. It is well documented that other oncogene products
such as the EGF receptor and c-erb-B protein are also
elevated in epithelial tumours (Ullrich et al., 1984; Merlino
et al., 1984; Berger et al., 1987; Cerny et al., 1986; Slamon et
al., 1987). For example, 80% of lung squa-mous celtpa show
high EGFR expression while 20% of breast ca have
amplified copies of the c-erb-B gene (Berger et al., 1987;
Cerny et al., 1986; Slamon et al., 1987). The relationship
between these oncogene products and the IL-4R is unknown,
although since oncogenesis is probably a multistage process,
the presence of two or more such molecules may be required
for autonomous growth of tumour cells.
Our observations concerning the elevation of IL-4R on
carcinoma could be exploited in clinical medicine both in the
diagnosis and detection of disease and in in vivo antibody-
guided therapy. Recent data have shown that amplification
of certain oncogenes and their products correlates with
disease prognosis in breast, lung and bladder carcinoma
(Slamon et al., 1987; Berger et al., 1987; Harris et al., 1988).
Studies are therefore in- progress to determine whether the
level of expression of MR6-Ag/IL-4R can also be used as an
Figure 4 Gamma-camera scan (anterior) of patient with lung
carcinoma given 0.5mg "'In-labelled (1.2mCi) MR6 mono-
clonal antibody, taken immediately (a) and after 48h (b). In (a)
the antibody is distributed throughout the blood pool. In (b)
MR6 is localised within the tumour mass (arrow).
indicator of prognosis in neoplastic disease. In addition, once
the gene for this molecule has been cloned (work in
progress), gene amplification studies will also be performed.
Our preliminary immunoscintigraphic data suggest that
monoclonal antibodies to the IL-4R, such as MR6, may
prove to be useful tools for in vivo imaging of metastatic
disease. More importantly, perhaps, these antibodies could
be used as cytotoxic agents in in vivo immunotherapy -
targeting lethal radionuclides, toxins or drugs to the tumour
site. Furthermore, such reagents with specificity for the IL-
4R could have two important advantages when compared
with many of the monoclonal antibodies in current use.
Firstly, since MR6 has been shown to inhibit IL-4 induced
T-lymphocyte proliferation in vitro (Larche et al., 1988a) it
might exert a comparable effect on IL-4R bearing epithelial
cells in vivo and thus act as a direct cytostatic agent as well
as performing its role as a 'magic bullet'. Secondly, we have
shown that the MR6 antibody has an inhibitory effect on
the in vitro immune responsiveness of T and B lymphocytes
a
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(Larche et al., 1988a,b). This raises the intriguing possibility
that when administered in vivo the murine monoclonal
antibody MR6 might inhibit the immune response to itself,
thus avoiding the generation and subsequent problems of a
human anti-mouse Ig response in patients receiving immuno-
therapy (Courtenay-Luck et al., 1987).
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